13-[[3-chloro-5-(trifluoromethyl)phenyl]carbamoylamino]tridecanoic acid

13-[[3-chloro-5-(trifluoromethyl)phenyl]carbamoylamino]tridecanoic acid, also known as 7c, is a synthetic aryl-urea fatty acid derivative designed as an anticancer agent. It is a chain-contracted analogue of the C16 aryl-urea fatty acid (compound 2). The molecule functions by targeting the mitochondria of cancer cells, specifically disrupting the mitochondrial membrane potential and stimulating the production of reactive oxygen species (ROS). This mitochondrial interference triggers apoptotic cell death. In preclinical studies, particularly against MDA-MB-231 breast cancer cells, 7c demonstrated superior potency (IC50 4.8 μM for mitochondrial disruption) and improved drug-like properties compared to analogues with different carbon chain lengths, identifying it as a promising lead molecule for further oncological drug development.

Other names

C13-analogue 7cC-13-analogue 7cC 13-analogue 7caryl-urea fatty acid 7c